Methicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Methicillin-Resistant Staphylococcus aureus (MRSA) Report Overview

In the 7MM, there were 714,131 hospitalized incident cases of Methicillin-Resistant Staphylococcus aureus (MRSA) in 2023. The hospitalized incident cases of Methicillin-Resistant Staphylococcus aureus (MRSA) will register an AGR of more than 1% during 2023-2033. Methicillin-resistant Staphylococcus aureus (MRSA) is a virulent, antibiotic-resistant bacteria that is associated with considerable morbidity and mortality. MRSA can be categorized according to the setting in which the infection was acquired, as either healthcare-associated MRSA (HA-MRSA), which is acquired in hospitals or nursing homes, or community-associated MRSA.

Methicillin-Resistant Staphylococcus aureus (MRSA) Market Outlook, 2023-2033 (Hospitalized Incident Cases)

Methicillin-Resistant Staphylococcus aureus (MRSA) Market Outlook, 2023-2033 (Hospitalized Incident Cases)

Buy the Full Report for More Insights into the Methicillin-Resistant Staphylococcus aureus Market Forecast

Download a Free Report Sample

The Methicillin-Resistant Staphylococcus aureus (MRSA) market research report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for MRSA in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the hospitalized incident cases of MRSA, segmented by sex and age (0–17 years, 18–64 years, and ≥65 years).

Market Size (2022) 714,131 Cases
AGR (2023-2033) >1%
Forecast Period 2023 – 2032
Key Countries ·       The US

·       France

·       Germany

·       Spain

·       Italy

·       The UK

·       Japan

Key Sex Segments ·       Men

·       Women

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Methicillin-Resistant Staphylococcus aureus (MRSA) Market Segmentation by Country

The key countries across the 8MM are the US, France, Germany, Spain, Italy, the UK, and Japan. In 2023, the US accounted for the highest percentage of hospitalized incident cases of MRSA in the 7MM. However, Spain is expected to have the highest AGR during the forecast period.

`Methicillin-Resistant Staphylococcus aureus (MRSA) Market Analysis by Country, 2023 (%)

`Methicillin-Resistant Staphylococcus aureus (MRSA) Market Analysis by Country, 2023 (%)

Buy the Full Report for More Country Insights into the MRSA Market

Download a Free Report Sample

Methicillin-Resistant Staphylococcus aureus (MRSA) Market Segmentation by Sex

Based on sex, the multiple myeloma vaccine market can be segmented into men and women. In 2023, the hospitalized incident cases of MRSA in the 7MM were higher in men than women. Among the 8MM, Spain had the largest difference in the hospitalized incident cases of MM between men and women. Among the 7MM, Japan had the largest difference in hospitalized incident cases of MRSA between men and women.

Methicillin-Resistant Staphylococcus aureus (MRSA) Market Analysis by Sex, 2023 (%)

Methicillin-Resistant Staphylococcus aureus (MRSA) Market Analysis by Sex, 2023 (%)

Buy the Full Report for More Sex Insights into the MRSA Market

Download a Free Report Sample

Segments Covered in the Report

Methicillin-Resistant Staphylococcus aureus (MRSA) Market Country Outlook (Hospitalized Incident Cases)

  • The US
  • France
  • Germany
  • Spain
  • Italy
  • The UK
  • Japan

Methicillin-Resistant Staphylococcus aureus (MRSA) Market Sex Outlook (Hospitalized Incident Cases)

  • Men
  • Women

Scope

  • The methicillin-resistant Staphylococcus aureus (MRSA): Epidemiology Report and Model provide an overview of the risk factors, comorbidities, and global trends of MRSA in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report includes a 10-year epidemiology forecast for the hospitalized incident cases of MRSA, segmented by sex and age (0–17 years, 18–64 years, and ≥65 years).
  • The hospitalized incident cases are further segmented by infection site (site A infections, which consist of types of pneumonia, skin, and soft tissue infections [SSTIs], and bloodstream infections [BSIs], and other infection sites, as well as site B infections, which included endocarditis and osteomyelitis).
  • Additionally, the hospitalized incident cases are segmented by case definition (HA-MRSA and CA-MRSA) in these markets. The forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the forecast hospitalized incident cases of MRSA across these markets.

Reasons to Buy

The MRSA Epidemiology series will allow you to –

  • Develop business strategies by understanding the trends shaping and driving the global MRSA markets.
  • Quantify patient populations in the global MRSA markets to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MRSA therapeutics in each of the markets covered.
  • Understand the magnitude of the MRSA population by age, sex, type, and infection site.

Table of Contents

  • 1. About GlobalData
  • 2. List of Contents

    • 2.1. List of Tables
    • 2.2. List of Figures

  • 3. Methicillin-Resistant Staphylococcus aureus (MRSA): Executive Summary

    • 3.1. Catalyst
    • 3.2. Related reports
    • 3.3. Upcoming reports

  • 4. Epidemiology

    • 4.1. Disease background
    • 4.2. Risk factors and comorbidities
    • 4.3. Global and historical trends
    • 4.4. 7MM forecast methodology

      • 4.4.1. Sources

    • 4.5. Forecast assumptions and methods
    • 4.6. Forecast assumption and methods: hospitalized incident cases of MRSA
    • 4.7. Forecast assumptions and methods: hospitalized incident cases of MRSA by site A infection type
    • 4.8. Forecast assumptions and methods: hospitalized incident cases by site B infection type

  • 5. Epidemiological forecast for MRSA (2023–33)

    • 5.1. Hospitalized incident cases of MRSA
    • 5.2. Age-specific hospitalized incident cases of MRSA
    • 5.3. Sex-specific hospitalized incident cases of MRSA
    • 5.4. Hospitalized incident cases of MRSA by type
    • 5.5. Hospitalized incident cases of MRSA by site A infection type
    • 5.6. Hospitalized incident cases of MRSA by site A infection type – pneumonia subtype
    • 5.7. Hospitalized incident cases of MRSA by site B infection type

  • 6. Discussion

    • 6.1. Epidemiological forecast insight
    • 6.2. COVID-19 impact
    • 6.3. Limitations of the analysis
    • 6.4. Strengths of the analysis

  • 7. Appendix

    • 7.1. Bibliography
    • 7.2. About the Authors

      • 7.2.1. Epidemiologist
      • 7.2.2. Reviewers
      • 7.2.3. Vice President of Disease Intelligence and Epidemiology
      • 7.2.4. Global Head of Pharma Research, Analysis and Competitive Intelligence

  • 8. Contact Us

Table

Table 1: Summary of added and removed data types

Table 2: Summary of updated data types

Table 3: Risk factors and comorbidities for MRSA

Figures

Figure 1: 7MM, hospitalized incident cases of MRSA, both sexes, N, all ages, 2023 and 2033

Figure 2: 7MM, hospitalized incidence of MRSA, men and women, cases per 100,000 population, all ages, 2023

Figure 3: 7MM, sources used to forecast the hospitalized incident cases of MRSA

Figure 4: 7MM, sources used to forecast the hospitalized incident cases of MRSA by type

Figure 5: 7MM, sources used and not used to forecast the hospitalized incident cases of site A MRSA infection

Figure 6: 7MM, sources used to forecast the hospitalized incident cases of MRSA with endocarditis or osteomyelitis

Figure 7: 7MM, hospitalized incident cases of MRSA, N, both sexes, all ages, 2023

Figure 8: 7MM, hospitalized incident cases of MRSA by age, N, both sexes, 2023

Figure 9: 7MM, hospitalized incident cases of MRSA by sex, N, all ages, 2023

Figure 10: 7MM, hospitalized incident cases of MRSA by type, N, both sexes, all ages, 2023

Figure 11: 7MM, hospitalized incident cases of MRSA based on site A infection type, N, both sexes, all ages, 2023

Figure 12: 7MM, hospitalized incident cases of MRSA with pneumonia by subtype, N, both sexes, all ages, 2023

Figure 13: 7MM, hospitalized incident cases of MRSA with infection B subtype, N, both sexes, all ages, 2023

Frequently asked questions

Methicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Methicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Methicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033 in real time.

  • Access a live Methicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.